Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.

Autor: Faingezicht I (AUTHOR), Avila-Aguerro ML (AUTHOR), Cervantes Y (AUTHOR), Fourneau M (AUTHOR), Costa Clemens SA (AUTHOR)

Publikováno v: Pan American Journal of Public Health / Revista Panamericana de Salud Pública. Oct2002, Vol. 12 Issue 4, p247-257. 11p.

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Autor: Costa Clemens SA; Department of Paediatrics, University of Oxford, Oxford, UK; Institute for Global Health, Siena University, Siena, Italy., Jepson B; Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bhorat QE; Soweto Clinical Trials Centre, Soweto, Gauteng, South Africa., Ahmad A; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Akhund T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Bansal H; Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Kelly EJ; Formerly Translational Medicine, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Khan M; Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON, Canada., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Chinese Academy of Medical Science, Oxford Institute, University of Oxford, Oxford, UK., Lombaard JJ; Josha Research, Bloemfontein, Free State, South Africa., Matthews S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Pipolo Milan E; Centro de Estudos e Pesquisas em Moléstias Infec, Centro de Pesquisas Clínicas de Natal, Natal, Rio Grande do Norte, Brazil., Olsson U; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Moura de Oliveira Paiva MS; Instituto Atena de Pesquisa Clínica, Natal, Rio Grande do Norte, Brazil., Seegobin S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Shoemaker K; Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Szylak A; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Mississauga, ON, Canada., Villafana T; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Green JA; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: justin.green@astrazeneca.com.

Publikováno v: The Lancet. Microbe [Lancet Microbe] 2024 Aug; Vol. 5 (8), pp. 100863. Date of Electronic Publication: 2024 Jun 12.

Development of a composite scoring system to rank communities at high risk of zero-dose children in Cameroon: A geospatial analysis.

Autor: Saidu Y; Clinton Health Access Initiative Inc., Yaoundé, Cameroon.; Institute for Global Health, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy., Agbor VN; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK., Di Mattei P; Gavi, the Vaccine Alliance, Geneva, Switzerland., Nchinjoh SC; Clinton Health Access Initiative Inc., Yaoundé, Cameroon., Edwidge NN; Clinton Health Access Initiative Inc., Yaoundé, Cameroon., Njoh AA; Expanded Program on Immunization, Cameroon Ministry of Public Health, Yaoundé, Cameroon.; School of Global Health and Bioethics, Euclid University, Bangui, Central African Republic., Muteh NJ; Gavi, the Vaccine Alliance, Geneva, Switzerland., Prescott M; Global Analytics and Implementation Research Team, Clinton Health Access Initiative Inc., Boston, USA., Wiwa O; Clinton Health Access Initiative Inc., Yaoundé, Cameroon., Diack D; Gavi, the Vaccine Alliance, Geneva, Switzerland., Flegere J; Gavi, the Vaccine Alliance, Geneva, Switzerland., Montomoli E; Institute for Global Health, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.; VisMederi srl, Siena, Italy., Costa Clemens SA; Institute for Global Health, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.; Department of Pediatrics, University of Oxford, Oxford, UK., Clemens R; Institute for Global Health, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.; International Vaccine Institute, IVI, Seoul, Republic of Korea.

Publikováno v: Journal of global health [J Glob Health] 2023 Nov 17; Vol. 13, pp. 04136. Date of Electronic Publication: 2023 Nov 17.

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Autor: Costa Clemens SA; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; Institute for Global Health, University of Siena, Siena, Italy., Marchevsky N; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Kelly S; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Felle S; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Eldawi A; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Rajasingam R; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Mahmud R; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Lambe T; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK., Voysey M; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Gonzalez I; Institute for Global Health, University of Siena, Siena, Italy., Milan EP; Centro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil., Justino MC; Instituto Evandro Chagas, Health Surveillance Secretariat, Brazilian Ministry of Health, Ananindeua, Pará, Brazil., Bibi S; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Aley P; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Clemens R; GRID RIO, Rio de Janeiro, Brazil., Pollard AJ; Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Aug 01; Vol. 19 (2), pp. 2233400.

Investigating the Possible Reasons for the Low Reported Morbidity and Mortality of COVID-19 in African Countries: An Integrative Review.

Autor: Manna OK; From the Institute for Global Health, University of Siena, Siena, Italy., Costa Clemens SA; From the Institute for Global Health, University of Siena, Siena, Italy.; University of Oxford, Oxford Vaccine Group, England, United Kingdom., Clemens R; From the Institute for Global Health, University of Siena, Siena, Italy.

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2023 Jul 01; Vol. 42 (7), pp. e222-e228. Date of Electronic Publication: 2023 Apr 03.